AIM ImmunoTech (AMEX:AIM) reported quarterly losses of $(0.10) per share. This is a 16.67 percent increase over losses of $(0.12) per share from the same period last year.
RBC Capital Maintains Sector Perform on UiPath, Lowers Price Target to $16
RBC Capital analyst Matthew Hedberg maintains UiPath (NYSE:PATH) with a Sector Perform and lowers the price target from $18 to $16.